Solo-GP, conviction-driven seed investor where Ullas Naik applies 25+ years’ crossover experience and extends intensive early operational support, structured tools, and candid guidance to support outlier founders scale. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
1CC.VC, a digital asset trading framework that delivers users with access to a expansive range of digital assets, encompassing cryptocurrencies, stablecoins, and tokens, continues to make its mark. The framework is built to be user-friendly and capabilities a variety of features, such as charting instruments, real-time trading, margin trading, and sophisticated order types. Furthermore, 1CC.VC also capabilities a variety of educational assets to help users learn more about digital assets and trading. The platform is built on top of a protected and dependable infrastructure, and its solutions are available in both English and Chinese.
Venture studio and fund that co‑incubates with LifePoint executives, giving startup ventures direct access to a $50B+ health system for pilot deployment, real‑world validation, and underserved population focus. Through targeted capital deployment, the fund plays an active role in the startup ecosystem.
30n operates as a venture fund geared toward investing in early-phase emerging ventures with a mission to create an equitable and sustainable future. They invest in a suite of industries, including technology, media, health care, and finance, and are driven to creating long-term value for their portfolio ventures. Their portfolio includes companies working on aI-powered technology, health tech, software, hardware, and more. Furthermore, fund also delivers resources to their portfolio ventures such as mentorship, network access, and strategic advice. 30n maintains a presence in San Francisco, New York, and London.
Early-phase partner for founders building iconic, industry-transforming companies, demonstrated by two new funds totaling $347M. With a disciplined investment approach, the team drives value for both founders and investors.
Acts as a VC and venture studio—co-founds emerging ventures with 25–30% of capital, assembles top‑1% specialists, and builds national‑capability defense, industrials, and bio‑infrastructure companies with corporate partners. The firm continues to build its presence across the venture capital landscape.
Women-led VC systematically backs clinically rigorous, behaviorally grounded wellbeing nascent-stage companies tackling stigmatized areas—alcohol use disorder, menopause, mental health—using stigma as an investing edge and insisting on consumer-grade UX. With a disciplined investment approach, the team drives value for both founders and investors.
